Physician profile
Gamal S Eskander
NPI 1659351542
$1,236.15
in general payments reported to CMS, 2019-2025
23 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $106 · 2022: $49.93 · 2023: $311 · 2024: $499 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $147.37 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $99.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $94.36 | 2024 | Voquezna |
| Pfizer INC. | $74.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $72.22 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $44.33 | 2022-2024 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $42.13 | 2024-2025 | Ingrezza |
| Inspire Medical Systems, INC. | $41.19 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $39.26 | 2023 | Gvoke Hypopen |
| Insulet Corporation | $38.98 | 2023 | Omnipod |
| Amgen INC. | $34.41 | 2024 | Krystexxa, Repatha, Otezla |
| Antares Pharma, INC. | $26.31 | 2024 | Xyosted |
| Edwards Lifesciences Corporation | $20.76 | 2025 | |
| Tempus Ai, INC | $20.13 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $19.97 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $16.56 | 2022 | |
| Dexcom, INC. | $15.72 | 2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $15.54 | 2023 | Korlym |
| Abbvie INC. | $15.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.71 | 2024 | Breztri |
| Exact Sciences Corporation | $13.64 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $6.06 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gamal Eskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.